Weekly Digest – December 2024 Weekly Digest – December 2024 16 Dec 2024: Biocytogen announces Adcendo ApS exercises antibody option to accelerate ADC development Biocytogen Pharmaceuticals announced that Adcendo ApS has exercised its option under a research, option, and license […]
Weekly Digest – December 2024 Weekly Digest – December 2024 18 Dec 2024: MediLink announces YL201 granted orphan-drug designation by the US FDA MediLink Therapeutics announced that the FDA has granted Orphan-Drug Designation to YL201 for the treatment of small […]
Weekly Digest – December 2024 Weekly Digest – December 2024 17 Dec 2024: FDA grants breakthrough therapy designation to sacituzumab govitecan for second-line ES-SCLC The FDA granted breakthrough therapy designation to sacituzumab govitecan-hziy for patients with extensive-stage small cell lung […]
Weekly Digest – December 2024 Weekly Digest – December 2024 16 Dec 2024: GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer The European Medicines Agency (EMA) granted PRIME Designation to GSK’227, […]
Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: Next-generation ADC treatments that will overcome the limitations and resistance of existing ADCs Innovotherapeutics has signed a joint research and technology transfer option contract with Riga Chem […]
Weekly Digest – December 2024 Weekly Digest – December 2024 07 Dec 2024: Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio Suven Pharmaceuticals acquired a 56% controlling stake in NJ Bio Inc, a US-based CRDMO specializing in antibody-drug conjugates […]
Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: GSK multiple myeloma drug’s DREAMM comeback continues with phase 3 data at ASH GSK’s Blenrep extended progression-free survival (36.6 months vs. 13.4 months) and duration of response […]
Weekly Digest – December 2024 Weekly Digest – December 2024 08 Dec 2024: Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with […]
Weekly Digest – December 2024 Weekly Digest – December 2024 10 Dec 2024: NextCure announces acceptance of IND application for LNCB74 NextCure announced that the FDA accepted its Investigational New Drug (IND) application for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) […]
Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Datopotamab deruxtecan (Dato-DXd) has received Breakthrough Therapy Designation […]
